A single center, randomized, double-blind, placebo-controlled, Phase Ib study to evaluate the chemoprotective antimalarial activity of a single dose of MMV390048 against controlled human malaria infection with Plasmodium falciparum sporozoite challenge in non-immune healthy adult volunteers